Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Saliogen Therapeutics is raising $125,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Raymond Tabibiazar played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Saliogen Therapeutics
SalioGen is advancing a new category of genetic medicine we call Gene Coding, which works by adding a new genomic code to turn on, off or modify the functions of new or existing genes. We are advancing potentially curative therapies, with an initial focus on developing durable, safe and accessible genetic medicine to more patients with inherited disorders. At SalioGen, we are driven not only by our efforts to realize the immense potential of our science, but also by our dedication and commitment to developing medicines that can make a significant impact on patients lives. Our Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes we call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.

To learn more about Saliogen Therapeutics, visit http://www.saliogen.com/

Contact:
Raymond Tabibiazar, Chief Executive Officer
857-990-2200
r.tabibiazar@saliogen.com
https://www.linkedin.com/in/ray-tabibiazar-a7b91b14/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved